300 related articles for article (PubMed ID: 22460421)
1. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care.
Kuter DJ; Mathias SD; Rummel M; Mandanas R; Giagounidis AA; Wang X; Deuson RR
Am J Hematol; 2012 May; 87(5):558-61. PubMed ID: 22460421
[TBL] [Abstract][Full Text] [Related]
2. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials.
George JN; Mathias SD; Go RS; Guo M; Henry DH; Lyons R; Redner RL; Rice L; Schipperus MR
Br J Haematol; 2009 Feb; 144(3):409-15. PubMed ID: 19016720
[TBL] [Abstract][Full Text] [Related]
3. A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial.
Mathias SD; Bussel JB; George JN; McMillan R; Okano GJ; Nichol JL
Clin Ther; 2007 May; 29(5):950-962. PubMed ID: 17697914
[TBL] [Abstract][Full Text] [Related]
4. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care.
Stasi R; Murali M; Michel M; Viallard JF; Giagounidis A; Janssens A; Legg J; Deuson R; Danese MD
Int J Hematol; 2012 Jul; 96(1):26-33. PubMed ID: 22562409
[TBL] [Abstract][Full Text] [Related]
6. Romiplostim: a review of its use in immune thrombocytopenia.
Keating GM
Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355
[TBL] [Abstract][Full Text] [Related]
7. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.
Mitsuhashi K; Ishiyama M; Imai Y; Shiseki M; Mori N; Teramura M; Seshimo A; Motoji T
Br J Haematol; 2012 Sep; 158(6):798-800. PubMed ID: 22758388
[No Abstract] [Full Text] [Related]
8. Romiplostim or standard of care in patients with immune thrombocytopenia.
Kuter DJ; Rummel M; Boccia R; Macik BG; Pabinger I; Selleslag D; Rodeghiero F; Chong BH; Wang X; Berger DP
N Engl J Med; 2010 Nov; 363(20):1889-99. PubMed ID: 21067381
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP).
Klaassen RJ; Mathias SD; Buchanan G; Bussel J; Deuson R; Young NL; Collier A; Bomgaars L; Blanchette V
Pediatr Blood Cancer; 2012 Mar; 58(3):395-8. PubMed ID: 21910213
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia.
Cines DB; Wasser J; Rodeghiero F; Chong BH; Steurer M; Provan D; Lyons R; Garcia-Chavez J; Carpenter N; Wang X; Eisen M
Haematologica; 2017 Aug; 102(8):1342-1351. PubMed ID: 28411254
[TBL] [Abstract][Full Text] [Related]
11. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
[TBL] [Abstract][Full Text] [Related]
12. Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.
Newland A
Eur J Haematol Suppl; 2009 Mar; (71):20-5. PubMed ID: 19200304
[TBL] [Abstract][Full Text] [Related]
13. [Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain].
López MF; Mingot ME; Valcárcel D; Vicente García V; Perrin A; Campos Tapias I
Med Clin (Barc); 2015 May; 144(9):389-96. PubMed ID: 24565604
[TBL] [Abstract][Full Text] [Related]
14. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J
J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524
[TBL] [Abstract][Full Text] [Related]
15. Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim.
Raval JS; Redner RL; Kiss JE
J Clin Apher; 2013 Aug; 28(4):321-4. PubMed ID: 23450778
[TBL] [Abstract][Full Text] [Related]
16. [New treatment options for primary immune thrombocytopenia].
Gudbrandsdottir S; Frederiksen H; Birgens HS; Nielsen CH; Nielsen OJ; Stentoft J; Hasselbalch HC
Ugeskr Laeger; 2011 Jan; 173(4):271-4. PubMed ID: 21262171
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.
Kikuchi K; Miyakawa Y; Ikeda S; Sato Y; Takebayashi T
BMC Health Serv Res; 2015 Jan; 15():2. PubMed ID: 25609557
[TBL] [Abstract][Full Text] [Related]
18. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
Chouhan JD; Herrington JD
Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
[TBL] [Abstract][Full Text] [Related]
19. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
Sivera P; Ruella M; Gueli A; Hu H; Wade M; Tarella C
Blood Coagul Fibrinolysis; 2012 Jun; 23(4):331-4. PubMed ID: 22343685
[TBL] [Abstract][Full Text] [Related]
20. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP).
Sanz MA; Aledort L; Mathias SD; Wang X; Isitt JJ
Value Health; 2011 Jan; 14(1):90-6. PubMed ID: 21211490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
